Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts

Summary: Pfizer just won a big fight to keep cheap copycats of its heart drug, Vyndamax, off the market until June 2031. This drug treats a serious heart condition called ATTR-CM and makes Pfizer billions of dollars.

This news is a mixed bag for a rival company, BridgeBio, which makes a competing drug called Attruby. On one hand, BridgeBio doesn't have to worry about cheap competition right away. On the other hand, investors were hoping the delay would last even longer, until 2033 or 2035. Because of this, BridgeBio's stock price dropped a little bit, even though their drug is still growing in popularity.

For more details, see rssapp-fiercepharma-com at fiercepharma.com/pharma/pfizer-fends-generic-competition-blockbuster-vyndamax-3-settlements (opens in new tab)